[{"id":"0dede7b9-ee1b-410d-9416-c7e60518928b","acronym":"NSGO","url":"https://clinicaltrials.gov/study/NCT03267589","created_at":"2025-08-02T14:05:36.136Z","updated_at":"2025-08-02T14:05:36.136Z","phase":"Phase 2","brief_title":"Trial in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03267589 - NSGO","lead_sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","biomarkers":" CD73","pipe":"","alterations":" ","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2021","study_completion_date":" 10/19/2021","last_update_posted":"2025-07-29"},{"id":"8cfca936-4075-4dd2-9674-338004715562","acronym":"","url":"https://clinicaltrials.gov/study/NCT02705482","created_at":"2021-01-18T13:12:35.282Z","updated_at":"2024-07-02T16:36:56.616Z","phase":"Phase 1","brief_title":"A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT02705482","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 03/30/2016","start_date":" 03/30/2016","primary_txt":" Primary completion: 08/07/2019","primary_completion_date":" 08/07/2019","study_txt":" Completion: 08/07/2019","study_completion_date":" 08/07/2019","last_update_posted":"2019-08-26"},{"id":"5c8aa153-2af3-4f87-9d6b-45ff09bb9885","acronym":"","url":"https://clinicaltrials.gov/study/NCT02318394","created_at":"2021-01-18T10:59:33.059Z","updated_at":"2024-07-02T16:37:14.426Z","phase":"Phase 1","brief_title":"A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT02318394","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" TILs","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 03/02/2015","start_date":" 03/02/2015","primary_txt":" Primary completion: 01/09/2018","primary_completion_date":" 01/09/2018","study_txt":" Completion: 01/09/2018","study_completion_date":" 01/09/2018","last_update_posted":"2018-01-29"}]